Ejaculatory disorder caused by alpha-1 adrenoceptor antagonists is not retrograde ejaculation but a loss of seminal emission
- PMID: 17010010
- DOI: 10.1111/j.1442-2042.2006.01535.x
Ejaculatory disorder caused by alpha-1 adrenoceptor antagonists is not retrograde ejaculation but a loss of seminal emission
Abstract
Aim: The etiology of the ejaculatory disorder induced by alpha-1 blockers is still controversial, although it has been suggested to be retrograde ejaculation. The aim of this study was to investigate the distribution of alpha-1 adrenoceptor subtype mRNA in human seminal vesicles, and to analyze the prevalence and etiology of the disorder in healthy men.
Methods: Experimental Study. Seminal vesicles from 10 surgical specimens (eight radical prostatectomy, two radical cystectomy) were dissected. Real-time PCR was conducted for quantification of mRNA expression of each alpha-1 adrenoceptor subtype. Clinical Study. Ejaculatory disorder was investigated using 17 healthy male volunteers. Tamsulosin (0.2 mg and 0.4 mg) and naftopidil (50 mg and 100 mg) were administered in a crossover manner for 3 days. The ejaculatory volume, sperm count in midstream urine after ejaculation, and fructose concentration in seminal plasma were investigated.
Results: Real-time PCR revealed that alpha-1a mRNA was significantly predominant in seminal vesicles (P < 0.001; 1a, 75.0%; 1b, 11.7%; 1d, 13.3%). Ejaculatory volume (baseline 2.72 +/- 0.28 mL) significantly decreased in the tamsulosin group (0.2 mg, 1.75 +/- 0.31 mL; 0.4 mg, 1.51 +/- 0.39 mL; P < 0.05), but not in the naftopidil group (50 mg, 2.70 +/- 0.24 mL; 100 mg, 2.48 +/- 0.26 mL; P = NS). There was no sperm in midstream urine after any ejaculation.
Conclusions: The current study demonstrates that alpha-1a mRNA is predominant among the adrenoceptor subtypes in human seminal vesicles. Decreased capacity of contraction of the seminal vesicles is proposed as the cause of the ejaculatory disorder induced by alpha-1 blockers.
Similar articles
-
Ejaculatory disorders caused by alpha-1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study.Urol Int. 2009;83(1):49-54. doi: 10.1159/000224868. Epub 2009 Jul 27. Urol Int. 2009. PMID: 19641359 Clinical Trial.
-
Impact of medical treatments for benign prostatic hyperplasia on sexual function.BJU Int. 2006 Apr;97 Suppl 2:34-8; discussion 44-5. doi: 10.1111/j.1464-410X.2006.06104.x. BJU Int. 2006. PMID: 16507052 Review.
-
Short- and long-term effects of silodosin, a selective alpha 1A-adrenoceptor antagonist, on ejaculatory function in rats.BJU Int. 2009 Jun;103(12):1680-5. doi: 10.1111/j.1464-410X.2009.08364.x. Epub 2009 Feb 10. BJU Int. 2009. PMID: 19220259
-
Change of expression levels of alpha1-adrenoceptor subtypes by administration of alpha1d-adrenoceptor-subtype-selective antagonist naftopidil in benign prostate hyperplasia patients.Prostate. 2007 Sep 1;67(12):1285-92. doi: 10.1002/pros.20624. Prostate. 2007. PMID: 17626248
-
[alpha1-adrenoceptor antagonists and ejaculation dysfunction].Zhonghua Nan Ke Xue. 2008 Apr;14(4):364-7. Zhonghua Nan Ke Xue. 2008. PMID: 18481434 Review. Chinese.
Cited by
-
The drug treatment of delayed ejaculation.Transl Androl Urol. 2016 Aug;5(4):576-91. doi: 10.21037/tau.2016.05.05. Transl Androl Urol. 2016. PMID: 27652229 Free PMC article. Review.
-
Evolving Role of Silodosin for the Treatment of Urological Disorders - A Narrative Review.Drug Des Devel Ther. 2022 Aug 26;16:2861-2884. doi: 10.2147/DDDT.S373659. eCollection 2022. Drug Des Devel Ther. 2022. PMID: 36051157 Free PMC article. Review.
-
The impact and management of sexual dysfunction secondary to pharmacological therapy of benign prostatic hyperplasia.Transl Androl Urol. 2017 Apr;6(2):295-304. doi: 10.21037/tau.2017.03.57. Transl Androl Urol. 2017. PMID: 28540239 Free PMC article. Review.
-
Update on the sexual impact of treatment for benign prostatic hyperplasia.Curr Urol Rep. 2012 Dec;13(6):433-40. doi: 10.1007/s11934-012-0278-5. Curr Urol Rep. 2012. PMID: 23065462 Review.
-
Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia.Clin Interv Aging. 2011;6:161-72. doi: 10.2147/CIA.S13803. Epub 2011 Jun 22. Clin Interv Aging. 2011. PMID: 21753871 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous